Skip to content

Study · Animal study (in vivo) · rat · 2010

7 results

Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts.

Ehrlich HP, Hazard SW 3rd

Annals of the New York Academy of Sciences1 Apr 2010Cited by 29 (Europe PMC)

PMID20536458 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05483.x (opens in a new tab)PepBankPUB-20536458
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, incisional wounds treated locally with Tbeta4 healed with minimal scarring.

    In plain wordsIn rats, wounds treated locally with thymosin beta‑4 healed with minimal scarring.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseScar formation in incisional wounds
    Study

    ratn: not reported in source

    Comparator
    Control incisions
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · localAs given in this study (rat).

    Source sentences

    Summary
    Incisional wounds in rats treated locally with thymosin beta4 (Tbeta4) healed with minimal scaring and without loss in wound breaking strength.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, Tbeta4-treated incisional wounds healed without loss in wound breaking strength.

    In plain wordsIn rats, wounds treated with thymosin beta‑4 healed without losing breaking strength.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeWound breaking strength
    Study

    ratn: not reported in source

    Comparator
    Control incisions
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · localAs given in this study (rat).

    Source sentences

    Summary
    Incisional wounds in rats treated locally with thymosin beta4 (Tbeta4) healed with minimal scaring and without loss in wound breaking strength.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, Tbeta4-treated incisional wounds were significantly narrower in width.

    In plain wordsIn rats, wounds treated with thymosin beta‑4 were narrower.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseWound width
    Study

    ratn: not reported in source

    Comparator
    Control incisions
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · localAs given in this study (rat).

    Source sentences

    Summary
    Treated wounds were significantly narrower in width.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, Tbeta4-treated wounds had better organized collagen fibers than controls, consistent with mature connective tissue.

    In plain wordsIn rats, wounds treated with thymosin beta‑4 had better organized collagen than control wounds.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCollagen fiber organization in wounds
    Study

    ratn: not reported in source

    Comparator
    Control incisions
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · localAs given in this study (rat).

    Source sentences

    Summary
    Polarized light microscopy treated wounds had superior organized collagen fibers, displaying a red birefringence, which is consistent with mature connective tissue. Control incisions had randomly organized collagen fibers, displaying green birefringence that is consistent with immature connective tissue.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats, Tbeta4-treated wounds had few myofibroblasts and fibroblasts with alpha smooth muscle actin stress fibers.

    In plain wordsIn rats, wounds treated with thymosin beta‑4 had few scar-forming myofibroblasts.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMyofibroblasts in treated wounds
    Study

    ratn: not reported in source

    Comparator
    Control incisions
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    Dose not stated · localAs given in this study (rat).

    Source sentences

    Summary
    Immunohistology treated wounds had few myofibroblasts and fibroblasts with alpha smooth muscle actin (SMA) stained stress fibers.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with subcutaneous sponge implants, Tbeta4 produced longer, thicker collagen fiber bundles than carrier on day 14.

    In plain wordsIn rats, thymosin beta‑4 led to longer, thicker collagen bundles in sponge implants than carrier alone.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseCollagen fiber bundles in sponge implants
    Study

    ratn: not reported in source

    Comparator
    Carrier
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    100 microg on days 2, 3 and 4 · Treatment on days 2, 3 and 4; assessed on day 14As given in this study (rat).

    Source sentences

    Summary
    Polyvinyl alcohol sponge implants placed in subcutaneous pockets received either carrier or 100 microg of Tbeta4 on days 2, 3, and 4. On day 14, treated implants revealed longer, thicker collagen fiber bundles with intense yellow-red birefringence by polarized light microscopy. In controls, fine, th…
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with subcutaneous sponge implants, few myofibroblasts appeared in Tbeta4-treated implants whereas controls contained mostly myofibroblasts.

    In plain wordsIn rats, sponge implants given thymosin beta‑4 had few myofibroblasts, while control implants had mostly myofibroblasts.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseMyofibroblasts in sponge implants
    Study

    ratn: not reported in source

    Comparator
    Carrier
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    100 microg on days 2, 3 and 4 · Treatment on days 2, 3 and 4; assessed on day 14As given in this study (rat).

    Source sentences

    Summary
    Controls contained mostly myofibroblasts, while few myofibroblasts appeared in Tbeta4 treated implants.
    1 context sentence
    Summary · context
    Polyvinyl alcohol sponge implants placed in subcutaneous pockets received either carrier or 100 microg of Tbeta4 on days 2, 3, and 4.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.